"So, the risks are very high..."
"The second option is biological therapy using interferon, which our team is also researching. It's a type of cytokine that can inhibit viral replication in tumor cells and cell division... However, its effects have been limited so far. Given the patient's condition, we can't guarantee complete suppression."
"The third option involves a negative immunoregulatory mechanism, a theory that the academic community has yet to reach a consensus on. This technology specifically targets HBV-related primary liver cancer. The problem is, no team has formally developed this mechanism yet. I've only discussed it once before, during an academic conference with Professor Jin from your university's College of Life Sciences."
